Pharming Group reports financial results for the first quarter of 2021
Results impacted by effects of COVID-19 in the US; recovery towards the end of Q1 2021 with expected return to growth in Q2 2021
LEIDEN, Netherlands, May 13, 2021 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its (unaudited) financial report for the first quarter of the year ended 31 March 2021. As previously announced, as of 1 January 2021, Pharming changed its presentation currency from Euro to US Dollars.
The Company will hold an analyst conference call at 13.30 CET/07.30 EST today. Dial in details can be found on page 6 of this report
Intravacc announces positive preclinical data for its OMV-based Lyme vaccine
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Intravacc announces positive preclinical data for its OMV-based Lyme vaccine
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
BILTHOVEN, Netherlands, April 7, 2021 /PRNewswire/ Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive preclinical results for its SARS-CoV-2 Outer Membrane Vesicle (OMV) based recombinant Spike protein (rSp) candidate nose spray vaccine.
For the preclinical study four groups of mice and four groups of hamsters received two intranasal immunizations on day one and day 21. One group of mice and hamsters received a vaccine based on OMV s mixed with rSp (CovOMV) and the other a vaccine based on OMV s coupled to rSp based on Intravacc s proprietary OMV click technology (CovOMVclick). Control animals received respectively only OMV s or only rSp. On day 35 the mice blood samples were tested for virus neutralizing antibodies. The hamsters were challenged with SARS-CoV-2 on day 42 after blood collection. Over a period of seven days after challenges, thei
(1)
LEIDEN, Netherlands, April 7, 2021 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the filing of its Annual Report on Form 20-F for the year ended 31 December 2020 with the U.S. Securities and Exchange Commission (SEC), which is available on the Company s website www.pharming.com under Investors/SEC filings.
About Pharming Group N.V.
Pharming Group N.V. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.
The flagship of our portfolio is our recombinant human C1 esterase inhibitor (rhC1INH) franchise. C1INH is a naturally occurring protein that down regulates the complement cascade in order to control inflammation in affected tissues.